<DOC>
	<DOC>NCT00620061</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in patients with OBD.</brief_summary>
	<brief_title>Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Patient has completed 12 weeks of blinded treatment in the SPI/0211OBD0631 or SPI/0211OBD0632 study. Patient will continue to be treated consistently for chronic, noncancerrelated pain with any full agonist opiate and will continue opiate therapy for the duration of the study. Patient must be willing to continue to abstain from use of disallowed medications as defined per protocol. Patient has newly diagnosed impaired renal function identified at the Screening Visit (i.e., serum creatinine concentration &gt; 1.8 mg/dL). Patient has experienced an unexplained and/or clinically significant weight loss defined as &gt; 5% within 90 days prior to Screening Visit. Patient plans to participate in another trial with an investigational drug or device during the course of the extension study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>